Arcturus’ technologies are covered by its extensive patent portfolio (182 patents and patent applications, issued in the U.S., Europe, Japan, China and other countries). I believe that you're going to start human trials of this vaccine this summer. If successful, Arcturus could develop a vaccine capable of vaccinating millions of people for a fraction of the cost of traditional mRNA vaccines. The versatility of the STARR technology™ affords its ability upon delivery into the cell to generate a protective immune response or drive therapeutic protein expression to potentially prevent against or treat a variety of diseases.
Due to superior immune response and sustained protein expression, Arcturus's STARR Technology is expected to produce a vaccine response at much lower doses compared to traditional mRNA vaccines. A leader in ground-breaking research and translational innovation, Duke-NUS has gained international renown through its five signature research programmes and eight centres. You can follow Katherine Ross on Twitter at @byKatherineRoss. The partnership with Arcturus Therapeutics combines complementary strengths as we work together to fight this global outbreak,” said Professor Thomas M. Coffman, Dean of Duke-NUS Medical School. Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) stock jumped on Wednesday after the company announced that it would be joining the fight against the latest coronavirus. Joining me today is Arcturus Therapeutics CEO, Joe Payne, to discuss his company's Covid-19 vaccine. Biotech Arcturus Sees Stock Soar on Coronavirus Vaccine Pact. They worked with MERS, and SARS, and now Covid-19.

Copyright ©2020 Dow Jones & Company, Inc. All Rights Reserved. The process to go through the, development process, and ultimately the approval of a vaccine can take a considerable amount of time. Except as otherwise required by law, Arcturus disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise. Novavax BIO now offers on-demand online classes that can be taken anywhere, anytime and at your own pace. Our tools and initiatives on workforce development, diversity and inclusion are designed to advance a more globally competitive industry. SAN DIEGO and SINGAPORE, March 04, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics (the “Company”, NASDAQ: ARCT), a leading messenger RNA medicines company, and Duke-NUS Medical School (Duke-NUS), a research intensive, graduate entry medical school, today announced their partnership to develop a Coronavirus (COVID-19) vaccine for Singapore. Uh, we're fortunate to be working with them uh, because they, this is not their first epidemic, or, or pandemic in this case. “We have observed STARR technology in pre-clinical models to be effective at extraordinarily low doses -- greater than 30-fold more efficient than traditional mRNA. In a statement Wednesday morning, Arcturus (ticker: ARCT) said that it is partnering with the Singapore-based Duke-NUS Medical school to develop a vaccine for Covid-19. Accelerate Discovery. Novavax stock was up 170.9% so far this year as of Tuesday’s close, while Inovio stock, which surged 69.7% on Tuesday amid news that it plans to begin human trials of its vaccine in April, is up 125.8% on the year.

Arcturus Therapeutics Holdings Inc said on Tuesday the first group of ... like Moderna Inc’s COVID-19 vaccine candidate, uses mRNA, or messenger RNA, to inoculate against the coronavirus. Forward Looking StatementsThis press release contains forward-looking statements that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Clinical study data expected in Q4 2020 . The current trial includes two parts that will assess ARCT-021's dosing, safety and effectiveness in participants including older adults aged between 56 and 80 years. The Duke-NUS and Arcturus partnership could expedite a solution to this urgent need as we utilize STARR Technology™ to bring a vaccine candidate for clinical testing in the shortest time possible,” said Professor Ooi Eng Eong, Deputy Director of the Emerging Infectious Diseases programme at Duke-NUS. About Arcturus Therapeutics. Arcturus stock, which closed on Tuesday at $14.50, traded to as high as $20.80 in pre-market trading, though the surge moderated somewhat by the time the market had opened. Moderna stock is up 42.7% so far this year. The Arcturus manufacturing process has been applied in multiple large GMP batches of highly pure RNA in our LUNAR-OTC program. Join BIO as we champion for bringing new treatments to patients with serious medical conditions and to support policies that promote innovation and improve patient access. Photograph by Jeff Pachoud/AFP via Getty Images, testing a vaccine based on a similar modality. Arcturus’ diverse pipeline of RNA therapeutics includes programs to potentially treat Ornithine Transcarbamylase (OTC) Deficiency, Cystic Fibrosis, Coronavirus (COVID … In a note on Inovio on Wednesday, Stifel analyst Stephen Willey acknowledged that there was “no visibility into the pathway to longer-term value creation” in connection to the company’s Covid-19 vaccine, though said that government funding would hasten development and manufacturing of the vaccine. This copy is for your personal, non-commercial use only. Keith Speights (TMFFishBiz) May 27, 2020 at 12:35PM Author Bio. ContactArcturus TherapeuticsNeda Safarzadeh (858) 900-2682, LifeSci Advisors LLC Michael Wood (646) 597-6983, Duke-NUS Medical School CommunicationsLekshmy Sreekumar, Ph.D. (+65) “From a supply chain and distribution perspective, for government entities like Singapore…it’s much more straightforward to have a single shot, without necessitating a boost,” Payne said. Coronaviruses are transmitted between animals and people and can evolve into strains not previously identified in humans. We've detected you are on Internet Explorer. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. Join to get started today! Opportunities for women, Black and other minority populations in the growing Bio-economy.
Uh, we, and, and to confirm that we do indeed have a single shot uh, vaccine.

Fostering the Success of the Industry.

Yet the route for companies to actually profit from these vaccines remains unclear.

Amplify Returns. For the best experience, please update to a modern browser. Show full articles without "Continue Reading" button for {0} hours.

"Based on preclinical immunogenicity data, our self-replicating mRNA-based investigational vaccine could have a highly differentiated safety and efficacy profile, and may potentially allow vaccination at very low doses, and with a single administration," Arcturus Chief Executive Officer Joseph Payne said in a statement. The company is among several drugmakers racing to develop a safe and effective vaccine for the new coronavirus that has killed more than 735,000​ people globally. What Arcturus Therapeutics Brings to the Fight Against the Coronavirus. Action Alerts PLUS is a registered trademark of TheStreet, Inc. Friday Coronavirus Update: President Trump Says No Shutdown If Second Wave, Bill Gates Reveals His Five Favorite Books for Summer 2020, Staying at Home Is Good for Home Depot, Jim Cramer Says. BIO Member and group discounts available! Arcturus Therapeutics Announces that it has Initiated Dosing of its COVID-19 STARR™ mRNA Vaccine Candidate, LUNAR-COV19 (ARCT-021) in a Phase 1/2 study.